"instanceType","uuid:ID","id","rationale","versionIdentifier"
"StudyVersion","7e54405e-e9d2-471b-ab24-6081d8af3b4f","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
